Type 2 (non-insulin-dependent) diabetes mellitus is a progressive metabolic disorder arising from genetic and environmental factors that impair beta cell function and insulin action in peripheral tissues. We identified reduced diacylglycerol kinase d (DGKd) expression and DGK activity in skeletal muscle from type 2 diabetic patients. In diabetic animals, reduced DGKd protein and DGK kinase activity were restored upon correction of glycemia. DGKd haploinsufficiency increased diacylglycerol content, reduced peripheral insulin sensitivity, insulin signaling, and glucose transport, and led to age-dependent obesity. Metabolic flexibility, evident by the transition between lipid and carbohydrate utilization during fasted and fed conditions, was impaired in DGKd haploinsufficient mice. We reveal a previously unrecognized role for DGKd in contributing to hyperglycemia-induced peripheral insulin resistance and thereby exacerbating the severity of type 2 diabetes. DGKd deficiency causes peripheral insulin resistance and metabolic inflexibility. These defects in glucose and energy homeostasis contribute to mild obesity later in life.
INTRODUCTION
Type 2 diabetes constitutes a burgeoning epidemic, which is expected to afflict over 300 million individuals world-wide by 2015 (Zimmet et al., 2001) . Characteristic features include glucose intolerance, insulin resistance, hyperglycemia, and often hyperinsulinemia (Biddinger and Kahn, 2006) . Skeletal muscle insulin resistance and impaired beta cell function (Eriksson et al., 1989) , arising from a combination of genetic and environmental factors (Florez et al., 2003; Laakso, 2005) , are necessary for the development of type 2 diabetes. Although available therapies fail to completely normalize glycemia and insulin sensitivity in the long-run (Moller, 2001) , aggressive control of hyperglycemia partly improves whole-body insulin sensitivity and skeletal muscle glucose uptake (Rossetti et al., 1990; Zierath et al., 1994) and attenuates the development of chronic complications such as retinopathy, nephropathy, and neuropathy (UK Prospective Diabetes Study Group, 1998) .
Diacylglycerol (DAG) plays a role in lipid metabolism as a precursor of triglycerides and phospholipids and acts as a second messenger in cellular signaling. In rodents, glucose-induced insulin resistance is associated with a temporal increase in intracellular DAG mass (Kraegen et al., 2006) . A persistent increase in intracellular DAG promotes intracellular lipid accumulation and aberrant signal transduction through activation of protein kinase C (PKC) isoforms and insulin resistance (Itani et al., 2002; Montell et al., 2001) . The underlying mechanism for DAG-induced insulin resistance is incompletely understood, but increased PKCmediated serine phosphorylation of the insulin receptor (IR) and insulin receptor substrate 1 (IRS-1) and subsequent downregulation of glucose transport are implicated (Yu et al., 2002) . DAG is also phosphorylated to form phosphatidic acid (PA) to act as a lipid second messenger to regulate signals involved in metabolic and mitogenic responses, including phosphatidylinositol 4-phosphate 5-kinase, PKCz, and the mammalian target of rapamycin (Avila-Flores et al., 2005; Luo et al., 2004) . Intracellular DAG and PA levels are tightly controlled, and disturbances in this balance may impair cellular metabolism.
Phosphorylation of DAG to PA is catalyzed by diacylglycerol kinases (DGK), a family of enzymes acting as key attenuators of DAG signaling . DGK isoforms are of relevance for insulin action because DAG accumulation is associated with insulin resistance and impaired glucose uptake in skeletal muscle (Montell et al., 2001) . Ten mammalian DGK isoforms have been classified into five subgroups based on primary structure (Sakane et al., 2007) . DGK isoforms including a, d, 3, and z are expressed in skeletal muscle, suggesting isoform-specific function (Topham, 2006; van Blitterswijk and Houssa, 2000) . DGKs play a critical role in depleting DAG/increasing PA at specific intracellular sites, including plasma membrane, endoplasmic reticulum, Golgi apparatus, and nuclei (Nagaya et al., 2002; Topham et al., 1998) . The direct role of DGK isoforms in the development of insulin sensitivity and diabetes mellitus is unknown.
We used oligonucletide microarrays to identify defects in skeletal muscle from type 2 diabetic patients by examining geneexpression profiles (E-MEXP-1270) . This revealed that DGKd is downregulated in skeletal muscle from poorly controlled type 2 diabetic patients (Table S1 available online). DGKd was originally cloned from a human testis library and is highly expressed in skeletal muscle (Sakane et al., 1996) . A previous microarray analysis of vastus lateralis muscle from individuals participating in the HERITAGE Family Study shows that DGKd expression was increased in people who exhibited enhanced insulin sensitivity after exercise training (Teran-Garcia et al., 2005) , suggesting that increased skeletal muscle DGKd expression may be a marker of improved insulin action.
We show that DGKd protein expression and total DGK activity are reduced in skeletal muscle from type 2 diabetic patients and diabetic rodents and normalized upon correction of hyperglycemia. Reduced DGKd activity, either by chemical inhibition or by genetic ablation of the enzyme using DGKd haploinsufficient mice, causes aberrant insulin signaling, glucose uptake defects in skeletal muscle and adipose tissue, impaired whole-body insulin sensitivity, and obesity. Our findings suggest a previously unrecognized role for DGKd hyperglycemia-induced peripheral insulin resistance. Reduced DGKd may exacerbate the severity of type 2 diabetes.
RESULTS

Skeletal Muscle DGKd Protein Content and Activity Is Reduced in Type 2 Diabetes
We determined DGKd protein expression in lysates prepared from vastus lateralis skeletal muscle biopsies obtained from 11 type 2 diabetic and 11 nondiabetic participants with fasting blood glucose of 9.9 ± 1.2 and 5.3 ± 0.2 mmol/l, respectively. The clinical characteristics for this cohort are presented in Table  S2 . Skeletal muscle DGKd protein expression was reduced 37% ( Figure 1A ; p < 0.05) in type 2 diabetic subjects, while DGKa, 3, and z protein was unaltered ( Figure 1B) . Total skeletal muscle DGK activity was markedly decreased in type 2 diabetic patients ( Figure 1C ), suggesting that DGKd is the predominantly expressed DGK isoform contributing to total DGK activity in human skeletal muscle. Skeletal muscle DGKd protein expression was negatively correlated with fasting blood glucose (r = À0.50; p < 0.01) and HbA1 C (r = À0.60; p < 0.05) and tended to correlate with body mass index (r = À0.31; p = 0.08) and whole-body glucose utilization (r = 0.43; p = 0.06), but not fasting insulin or percentage body fat ( Figure S1 ). In a similar cohort of type 2 diabetic patients, skeletal muscle IR, IRS-1, IRS-2, MAP kinase, glycogen synthase, and glucose transporter 4 (GLUT4) protein content was unchanged, despite impairments in insulin signaling and glucose uptake (Krook et al., 2000) .
We hypothesized that DGKd protein expression may be directly related to the level of glycemia. We determined whether hyperglycemia directly downregulates DGKd protein expression in cultured human skeletal muscle from 5 nondiabetic participants incubated with either 5.5 mM or 25 mM glucose for 96 hr ( Figure 1D ). DGKd protein expression was downregulated in myotubes exposed to 25 mM glucose, while protein expression of DGKz was unaltered. To assess whether changes in glycemia regulate DGKd expression in vivo, we studied skeletal muscle from Goto Kakizaki (GK) rats, a nonobese normolipidemic animal model of type 2 diabetes developed by selective breeding of glucose-intolerant Wistar rats over several generations. This animal model is characterized by hyperglycemia and peripheral insulin resistance, primarily due to a beta cell defect (Portha, 2005) . Rats were treated for 4 weeks with phlorizin (phloretin-2 0 -b-glucoside), an inhibitor of renal glucose reabsorption to normalize glycemia, glucose tolerance, and insulin sensitivity (Krook et al., 1997; Song et al., 1999) . Skeletal muscle DGKd protein expression was decreased by 35% (p < 0.05) in GK rats versus nondiabetic Wistar rats ( Figure 1D ). In contrast, DGKz and a protein expression in GK rats was unaltered ( Figure S2 ), consistent with our human study, highlighting that the DGKd isoform is specifically downregulated in diabetes. Phlorizin treatment in diabetic GK rats normalized glycemia and restored DGKd protein expression. Total DGK activity ( Figure 1E ) and DAG mass ( Figure 1F) were measured. Total DGK activity was decreased and intracellular DAG mass was increased in skeletal muscle from diabetic GK rats, indicating that the DGKd isoform is a major contributor to total DGK activity in rodent skeletal muscle. Normalization of glycemia in phlorizin-treated GK rats restored skeletal muscle DGK activity and DAG mass. Conversely, liver expression of DGKd and DAG mass was similar between Wistar and GK rats treated with either vehicle or phlorizin ( Figure S3 ). In fat-fed Wistar rats, which display peripheral insulin resistance and glucose intolerance but not hyperglycemia, skeletal muscle DGKd protein expression was unaltered ( Figure 1H ). Thus, hyperglycemia directly influences DGKd protein expression, DGK activity, and DAG mass in skeletal muscle but not liver.
Inhibition of DGK Activity Decreases Glucose Transport through a DAG-cnPKC Pathway Alterations in skeletal muscle DGK activity change the local concentration of DAG and PA, which may subsequently influence insulin signaling and metabolism. We determined whether inhibition of DGK alters insulin action in intact rat epitrochlearis muscle using two pan-DGK class I inhibitors, R59949 or R59022 . These inhibitors bind to the catalytic domain of DGK isoforms and inhibit kinase activity. Incubation of rat epitrochlearis muscle with R59949 or R59022 decreased total DGK activity ( Figure 2A ) and increased DAG levels ( Figure 2B ), highlighting an inverse relationship between DGK activity and DAG accumulation in skeletal muscle. In parallel with the DAG accumulation, conventional/novel PKC (cnPKC) activity ( Figure 2C ) and isoform-specific phosphorylation of PKCd ( Figure 2D ) were increased. DGK inhibition did not alter IR tyrosine phosphorylation ( Figure 2E ) but increased IRS-1 Ser307 and Ser302 phosphorylation ( Figures 2F and 2G ), implicating DAG-induced PKC activity in the negative regulation of insulin signaling. Indeed, insulin action on IRS-1 tyrosine phosphorylation, IRS-1-associated phosphatidyl inositol (PI) 3-kinase activity, and Akt/PKB kinase phosphorylation was impaired in muscle exposed to the DGK inhibitors ( Figure 2H ). DGK inhibition also reduced insulin-stimulated glucose transport in isolated rat epitrochlearis muscle (Figures 2I and 2J) . To directly explore a role of DAG-induced PKC-mediated insulin resistance, muscles were coincubated with R59949 and the broad spectrum PKC inhibitor GF109203X ( Figures 2H and 2I ). Under these conditions, insulin action on IRS-1, PI 3-kinase, Akt, and glucose transport was restored. These results implicate increased DAG levels and PKC activity in the regulation of the insulin response.
To address whether the effect of DGK inhibitors on glucose transport is due to reduced insulin signaling or downstream effects on GLUT4 trafficking or activity, epitrochlearis muscle was exposed to hypoxia ( Figure 2J ), an insulin-independent mediator of GLUT4 translocation and glucose transport (Cartee et al., 1991) . Hypoxia-mediated glucose transport was unaltered in muscle coincubated with R59949; thus DGK inhibition does not appear to directly alter GLUT4 traffic. Moreover, GLUT4 protein expression was unaltered in muscle exposed to DGK inhibitors (data not shown).
To exclude a possible direct inhibitory effect of R59949 on other kinases along the insulin signaling pathway, a specificity test of the R59949 was performed against a panel of 30 protein kinases in an in vitro assay (Bain et al., 2003; Davies et al., 2000) . Among these kinases, only serum and glucocorticoid regulated kinase (SGK) was considerably inhibited by R59949 ( Figure S4 ). The specificity assays were conducted at an ATP concentration far lower than that which is present in cells. Since R59949 is likely to be an ATP competitive inhibitor, this compound is expected to be a far weaker inhibitor of SGK1 in cells. Indeed, phosphorylation of NDRG1, a specific substrate of SGK expressed in skeletal muscle (Murray et al., 2004) , was unaffected by the concentrations of R59949 used in this study. Moreover, skeletal muscle SGK protein expression was unaltered between type 2 diabetic versus control subjects, or Wistar versus diabetic GK rats. Addition of R59949 directly to the assay buffer did not alter PI 3-kinase activity ( Figure S4 ). Thus, the impairment in insulin signaling and glucose uptake is likely a direct consequence of DGK inhibition.
DGK Protein Expression and Activity in DGKd Haploinsufficient Mice
As there are several DGK isoforms expressed in skeletal muscle (a, d, 3 , and z), we cannot completely resolve whether chemical inhibitors of DGK activity will confer the same phenotype as DGKd isoform-specific inhibition. The DGK activity inhibited by either R59949 or R59022 is primarily derived from class I DGK isoforms . Although the DGK isoforms inhibited by either R59949 or R59022 appear to affect insulin signaling and glucose uptake, only DGKd, a class II DGK isoform, was reduced in type 2 diabetic patients and diabetic GK rats. To determine whether the reduction in DGKd protein expression in skeletal muscle from type 2 diabetic patients is of direct physiological relevance for altered glucose homeostasis, we metabolically characterized heterozygous DGKd whole-body knockout mice. DGKd +/À mice were generated as described (Crotty et al., 2006) . Inhibition of DGK activity by R59949 in skeletal muscle homogenates from either Wistar and GK rats or wild-type (WT) and DGKd +/À mice indicates that the DGKd isoform accounts for approximately 60% of total DGK activity ( Figure S5 ).
Figure 2. DGK Inhibition Attenuates Insulin Action in Rat Muscle
Isolated epitrochlearis muscle (n = 6-11) was incubated in the absence or in presence of 2.4 nM insulin and/or 25 mM R59949, 50 mM R59022, and/or 1 mM of PMA. Muscle homogenates were prepared for (A) total DGK activity, (B) DAG content, and (C) combined conventional and novel PKC activity analysis. Lysates were subjected to immunoblot analysis for (D) PKCd Thr505 phosphorylation, (E) IR tyrosine phosphorylation, (F) IRS-1 Ser307 phosphorylation, and (G) IRS-1 Ser302 phosphorylation. Skeletal muscle was also incubated (H-I) in the absence or presence of 1 mM PMA, 1 mM GF109203X, 25 mM R59949, or 50 mM R59022. (H) IRS-1 tyrosine phosphorylation, PI 3-kinase activity, Akt Ser473 phosphorylation, and (I-J) 3-O-methyl-glucose transport were assessed. Upper panel is representative image. Lower panel is mean ± SEM, *p < 0.05 versus non-insulin-stimulated control. # p < 0.05 versus insulin-stimulated.
DGKd +/À mice have a 50% reduction in DGKd protein in skeletal muscle ( Figure 3A) , which is similar to the 37% reduction in skeletal muscle DGKd protein expression in type 2 diabetic patients ( Figure 1A ). DGKd protein expression in fat and liver of DGKd +/À mice was also reduced ( Figures 3B and 3C ). Total DGK activity was reduced in skeletal muscle and fat but not liver ( Figure 3D ). Total DGK activity in homogenates and a crude membrane fraction obtained from gastrocnemius muscle from DGKd +/À mice was reduced, while DGK activity in the cytoplasmic fraction was unaltered ( Figure 3E ). The decrease in DGK activity in the membrane fraction in DGKd +/À mice highlights the potential importance of the membrane localization of DGKd signaling. DGKd contains a PH domain and has been found in endoplasmic reticulum and Golgi apparatus (Nagaya et al., 2002) . Subcellular fractionation of rat gastrocnemius muscle revealed that DGKd protein is mainly associated with intracellular membranes (data not shown).
DGKd Haploinsufficiency Leads to Development of Glucose Intolerance and Obesity
Age is an important risk factor for the development of skeletal muscle insulin resistance and type 2 diabetes (Nair, 2005) . Thus, DGKd +/À mice were studied at 9 or 36 weeks. Blood chemistry for DGKd +/À and WT littermates is presented (Table S3) . At 9 weeks, body weight and epidydimal fat pad weight were unaltered in DGKd +/À mice ( Figure 4A ). However, at 36 weeks, body weight and epidydimal fat pad weight were increased in DGKd +/À mice, concomitant with increase in plasma leptin concentration (Table S3 ). Plasma resistin concentration was unaltered in DGKd +/À mice but significantly increased at 36 week regardless of genotype (Table S3) . Plasma adiponectin levels were unaltered between DGKd +/À and WT mice (Table S3 ).
An intraperitoneal glucose tolerance test (IPGTT) was performed at 9 and 36 weeks. Glucose tolerance, fasting blood glucose, and plasma insulin levels were normal at 9 weeks in DGKd +/À mice (Figures 4B and 4C and Table S3 ). In contrast, glucose tolerance mates. These age-associated changes in glucose homeostasis were independent of any further reduction in DGKd expression or total DGK activity ( Figures 4D and 4E ). Skeletal muscle DAG levels were increased by 40% in DGKd +/À mice ( Figure 4F ), underscoring the contribution of DGKd to skeletal muscle DAG homeostasis. In contrast, DAG levels were unaltered in liver of DGKd +/À mice ( Figure S6 ), indicating that this isoform plays a minor role in total DGK activity in liver.
Insulin-stimulated glucose transport was assessed in isolated soleus muscle at 9 and 36 weeks in WT and DGKd +/À mice ( Figure 4G ). Despite normal fasting insulin, glucose tolerance, and body weight in DGKd +/À mice at 9 weeks, insulin-stimulated glucose transport in response to 0.36 nM, but not 120 nM, was decreased in isolated soleus muscle. Moreover, the impairment in skeletal muscle insulin-stimulated glucose transport was observed prior to the development of obesity, hyperinsulinemia, or glucose intolerance. An impairment in submaximal (0.36 nM), but not maximal (120 nM), insulin-stimulated glucose transport was noted in WT mice at 36 weeks. In DGKd +/À mice, basal glucose transport was unaltered at 36 weeks, but insulin-stimulated glucose transport was impaired, concomitant with obesity, hyperinsulinemia, and glucose intolerance, compared to agematched WT littermates. Skeletal muscle GLUT4 protein expression was unaltered between WT and DGKd +/À mice.
Consequence of DGKd Haploinsufficiency on Peripheral Insulin Sensitivity and Signaling
Since glucose uptake in skeletal muscle and adipose tissue accounts for the majority of peripheral glucose disposal, we examined tissue-specific responses for glucose uptake in vivo during a euglycemic-hyperinsulinemic clamp in conscious mice. We studied 9-week-old mice to avoid the potential deleterious effect of hyperinsulinemia and/or obesity on wholebody insulin-mediated glucose homeostasis, as these factors independently contribute to insulin resistance. Euglycemichyperinsulinemic clamps were performed in separate experiments using either a low (1.25 mU/min/kg; Figure 5A ) or high (10 mU/min/kg; Figure 5B ) dose insulin infusion. Under the low-dose insulin infusion ( Figure 5A ), plasma insulin levels were increased 2-fold (0.2 ± 0.1 versus 0.4 ± 0.06 ng/ml). Insulinmediated peripheral glucose utilization was increased 66% versus 18% over basal in WT versus DGKd +/À mice, respectively, whereas the hepatic insulin response was similar between genotypes. Under the high dose insulin infusion ( Figure 5B ), plasma insulin levels were markedly increased (0.4 ± 0.1 versus 5.2 ± 0.4 ng/ml), and hepatic glucose output was completely inhibited in both genotypes. Similar to results for the low-dose insulin infusion, peripheral glucose utilization was impaired in DGKd +/À mice.
In vivo tissue-specific glucose uptake was also determined in separate experiments under the high-dose insulin infusion (Figures 5C and 5D ). In DGKd +/À mice, insulin-stimulated glucose uptake ( Figure 5C ) was significantly decreased in EDL (34%) and soleus (21%) and tended to be decreased in gastrocnemius (36%, p = 0.09), diaphragm (36%, p = 0.12), and heart (29%, p = 0.07) muscle. Insulin-mediated glucose uptake was also significantly decreased in white adipose tissue (50%) but not brown adipose tissue (BAT) ( Figure 5D ). The impaired skeletal muscle glucose uptake was associated with reduced insulin-stimulated tyrosine phosphorylation of IR and IRS-1 and serine/threonine phosphorylation of Akt and AS160, components of the canonical insulin signaling cascade important for glucose uptake and metabolism ( Figure 5E ). In contrast, liver insulin-stimulated phosphorylation of IR, IRS-1, IRS-2, and Akt was similar between DGKd +/À and WT mice ( Figure 5F ). Thus, DGKd +/À mice develop insulin resistance in skeletal muscle and adipose tissue, but not liver, prior to development of obesity, glucose intolerance, and hyperinsulinemia. Since defects in glucose uptake were observed in isolated skeletal muscle, as well as at the wholebody level, DGKd expression directly influences skeletal muscle insulin sensitivity independent of alterations in the metabolic milieu. 
Skeletal Muscle Lipid Oxidation and Whole-Body Energy
Homeostasis Are Altered in DGKd +/À Mice We next determined whether DGKd expression influences skeletal muscle lipid metabolism or whole-body energy homeostasis. Skeletal muscle triglyceride content and plasma nonesterified fatty acid were unaltered between genotypes (Table S3) ; however, oleate oxidation was reduced 30% in isolated soleus muscle from 9-week-old DGKd +/À mice ( Figure 6A ). Wholebody energy homeostasis was also determined through analysis of food intake, locomotor activity, oxygen consumption, and respiratory exchange ratio (RER). Although food intake and locomotor activity did not differ between genotypes over a 24 hr period ( Figures 6B and 6C ), oxygen consumption (VO 2 ; ml/kg/hr) was reduced in DGKd +/À mice ( Figure 6D ). RER was determined in the light and dark cycles, when animals were in a rested and active state, respectively. DGKd +/À mice failed to appropriately shift between lipid and glucose oxidation in the transition between the light (rested) and dark (active) states ( Figure 6E ), thereby demonstrating ''metabolic inflexibility.'' Changes in skeletal muscle oleate oxidation and whole-body energy homeostasis were observed prior to the development of obesity. 
Signaling Impairments in Skeletal Muscle
2002). Expression and phosphorylation of DAG-dependent
PKCs and IRS-1 were determined in skeletal muscle ( Figure 7 ) and liver ( Figure S6 ) from DGKd +/À mice and WT littermates.
Phosphorylation and expression of PKC q and h were unaltered in skeletal muscle from DGKd +/À mice. Phosphorylation of PKCd was increased in skeletal muscle from DGKd +/À mice ( Figure 7A ), similar to the effect of DGK inhibition by R59949. Protein expression of IR and IRS-1 ( Figures 7B and 7C ) was reduced in DGKd +/À mice at 9 weeks but not 36 weeks. IR and IRS-1 expression in both genotypes at 36 weeks was lower compared to 9 weeks. IRS-1 Ser307 phosphorylation normalized to the level of IRS-1 protein expression was increased in DGKd +/À mice ( Figure 7D ). In stark contrast to the phenotype described for skeletal muscle, liver DAG content, PKCd phosphorylation, and IR and IRS protein expression were unaltered in DGKd +/À mice ( Figure S6 ). Liver insulin signaling was unaltered in DGKd +/À mice after the euglycemichyperinsulinemic clamp, consistent with the observation that peripheral, but not hepatic, insulin sensitivity was impaired. Collectively these data indicate that a reduction in DGKd impairs insulin signaling in skeletal muscle.
Genetic Analysis of DGKD
We analyzed quantitative traits for the DGKD gene in 234 offspring of type 2 diabetic patients who had a nondiabetic oral glucose tolerance test. One of the parents had to have type 2 diabetes and the other had to exhibit normal glucose tolerance. Nine single-nucleotide polymorphisms (SNPs) properly covering the promoter and coding regions of DGKD were screened. Different SNPs had a nominal association (p < 0.05) with insulin area under the curve (AUC) in a 2 hr oral glucose tolerance test, glucose AUC during the intravenous glucose tolerance test (IVGTT), and insulin AUC from 10 to 60 min in an IVGTT (Table  S4) . No association was observed between DGKD SNPs and insulin sensitivity, as measured by the euglycemic clamp.
DISCUSSION
Intracellular DAG levels are elevated in skeletal muscle from insulin-resistant rodents and humans (Itani et al., 2002; Kraegen et al., 2006) , suggesting a role for lipid intermediates in the development of insulin resistance. DGK isoforms modulate the balance between DAG and PA levels and terminate DAG signals through the conversion of DAG to PA (Sakane et al., 2007; Topham, 2006) . DGK isoforms interact with specific isoforms for PKC, RasGRP, and PI kinases to regulate numerous biological events including cell growth, neuronal transmission, and cytoskeleton remodeling (Sakane et al., 2007; Topham, 2006) . We reveal a previously unrecognized role for DGKd in contributing to hyperglycemia-induced insulin resistance and impairments in energy homeostasis, thereby exacerbating the severity of type 2 diabetes. Reduced DGKd activity, either by chemical inhibition or by genetic ablation of the enzyme using DGKd +/À mice, caused aberrant insulin signaling, glucose uptake defects in skeletal muscle and adipose tissue, impaired whole-body insulin resistance, and obesity. Our findings in DGKd +/À mice demonstrate that reduced DGKd expression directly causes peripheral insulin resistance, metabolic inflexibility, mild obesity, and further metabolic derangements. Skeletal muscle protein expression of DGKd and total DGK activity was reduced in type 2 diabetic patients and diabetic rodents and normalized upon correction of hyperglycemia. This finding strongly suggests that DGKd undergoes downregulation as a consequence of the altered metabolic milieu. Indeed DGKd, but not a, 3, or z, protein expression was negatively correlated with fasting glucose and HbA 1c . These defects were localized to peripheral, rather than hepatic, tissues. Although variations at the DGKD locus are unlikely to constitute a major genetic cause of type 2 diabetes (Saxena et al., 2007; Sladek et al., 2007) , we found suggestive evidence that SNPs of DGKD are associated with altered glucose metabolism in offspring of type 2 diabetic subjects. DGKd appears to play an important role in metabolic regulation since environmental factors can also contribute to regulation of insulin sensitivity in type 2 diabetes. Exercise traininginduced improvements in insulin sensitivity have been positively correlated with an increase in skeletal muscle DGKd gene expression in nondiabetic (Teran-Garcia et al., 2005) and type 2 diabetic (Fritz et al., 2006) people, highlighting a potential role of this enzyme in the regulation of metabolism in response to regular exercise. Rare genetic defects in DGKD have been observed; a recent case study of a 12-year-old-female with epilepsy provides genetic support that disruption on DGKD is associated with seizures, capillary abnormality, developmental delay, infantile hypotonia, and obesity (Leach et al., 2007) . While the DGKd +/À mice studied here also displayed an obesity phenotype with aging, they did not display any obvious growth defects or sign of seizures. Insulin sensitivity is impaired in younger DGKd +/À mice that are not obese and have yet to show any signs of hyperglycemia, glucose intolerance, systemic hyperinsulinemia, or alterations in food intake and locomotor activity. DGKd haploinsufficiency can cause ''primary'' peripheral insulin resistance, impaired lipid oxidation, and impaired energy homeostasis, which leads to obesity in later life. Insulin-mediated glucose uptake and uncoupling protein 1 protein expression in BAT were unaltered between genotypes, providing evidence against metabolic alterations in BAT as a cause of the obesity phenotype in DGKd +/À mice. Furthermore, hypothalamic mRNA expression of neuropeptides including neuropeptide Y, proopiomelanocortin, and agouti-related protein is unaltered in DGKd +/À mice, despite mild obesity and insulin resistance with aging. These results do not preclude an effect of DGKd in energy homeostasis via actions in other tissues.
The reduction in DGKd expression and activity appears to promote peripheral insulin resistance and metabolic inflexibility, which may contribute to the obesity phenotype. Metabolic inflexibility, as defined by an inability to appropriately transition between lipid and carbohydrate oxidation, has been linked to impaired oxidative capacity in insulin resistance and type 2 diabetes (Storlein et al., 2004) . Impaired oleate oxidation and peripheral insulin-mediated glucose uptake in DGKd +/À mice were associated with increased adipose mass and increased body weight, which further contributed to the development of glucose intolerance. These defects may arise from alterations in mitochondrial size and density, expression of oxidative enzymes, or changes in skeletal muscle fiber type. Therefore, DGKd +/À mice resemble many of the features associated with the clinical manifestation of peripheral insulin resistance in type 2 diabetes in humans. Disruption of insulin signaling events associated with GLUT4 translocation impairs glucose transport (Ishiki and Klip, 2005) . Based on our clinical and experimental studies, we describe a signal transduction pathway involving DAG-induced insulin resistance as a result of impaired DGKd expression and activity. In addition to a local increase in DAG, a decrease in DGKd expression and DGK activity leads to a concomitant decrease in PA levels. DGK enzymes act as both terminators of DAG-mediated signals and activators of PA-mediated signals. Protein targets of PA include positive regulators of glucose transport, such as PKCz, and membrane vesicle traffic, such as phosphatidylinositol 4-phosphate 5-kinase (Sakane et al., 2007; Topham and Prescott, 1999) . Interestingly, insulin-independent glucose transport was unaltered by DGK inhibition. Nevertheless, we cannot exclude the possibility that the reduction of DGKd contributes to the regulation of glucose transport through regulating the production of PA.
The increase in DAG mass and PKC activity offers a possible mechanism for the decreased insulin signaling in DGKd +/À mice. The impairment in whole-body insulin-mediated glucose uptake may be attributed to DAG accumulation, elevated PKC activity, and serine phosphorylation of IRS-1, leading to peripheral insulin resistance and impaired energy homeostasis. Reduced membrane-associated DGK activity may change subcellular localization and compartmentalization of important signal transducers and contribute to an altered metabolic response. Confirming an effect of DGKd deficiency on tyrosine receptormediated signaling, DAG-induced PKC activation increases epidermal growth factor receptor threonine phosphorylation and reduces receptor expression and activity in keratinocytes from DGKd null mice (Crotty et al., 2006) . This provides a link between DGKd, PKCs, and consequently EGFR and insulin signaling pathways. Interestingly, differences between chemical inhibition of DGK and heterozygosity for DGKd with respect to IR expression and phosphorylation were noted, suggesting that reduced IR protein expression in DGKd +/À mice may arise from chronic transcriptional effects as observed for EGFR in DGKd null mice. Our results cannot exclude the possibility that reduced IR expression contributes to the observed impairments in insulin sensitivity and glucose homeostasis in DGKd +/À mice. Musclespecific IR dominant-negative transgenic mice (Chang et al., 1994; Moller et al., 1996) or IR null mice (Bruning et al., 1998) develop mild obesity secondary to defects in skeletal muscle insulin action. Reduced DGKd protein expression directly contributes to the development of peripheral insulin resistance and mild obesity. Data from DGKd +/À mice support this concept, as a 50% reduction in DGKd protein expression induces peripheral insulin resistance and mild obesity in the absence of hyperglycemia. Reduced DGKd protein expression can act as a primary mediator of insulin resistance in type 2 diabetes and promote mild obesity with aging. Data from diabetic GK rats also provide evidence that insulin resistance occurs in concert with hyperglycemia-induced downregulation of DGKd. In this case, the reduction in DGKd protein occurs in response to hyperglycemia or other environmental factors, which secondarily impact DGKd expression and DAG metabolism. Collectively, our findings highlight a role for DGKd in the regulation of hyperglycemia-induced impairments in peripheral insulin sensitivity and reveal new insight into how to resolve the metabolic complexities associated with type 2 diabetes mellitus. Therapeutic approaches to target DAG and PA metabolism via regulation of DGKd may control and prevent insulin resistance in metabolic disease.
EXPERIMENTAL PROCEDURES
Human Studies for Muscle Analysis Subjects were matched for age, BMI, and physical fitness. Skeletal muscle biopsies were obtained from the vastus lateralis portion of the quadriceps muscle from 11 type 2 diabetic and 11 healthy control subjects (Table S2 ) with approval from the institutional ethical committee of Karolinska Institutet. Studies were performed according to the declaration of Helsinki and informed written consent was obtained. Type 2 diabetic subjects were treated with diet, sulfonylureas, or metformin. Individuals taking beta-adrenergic receptor blockers, ACE inhibitors, or hormonal therapy were excluded from the study. Skeletal muscle lysates were prepared and subjected to immunoblot analysis as described (Krook et al., 2000) .
Subjects and Phenotype Analysis for Genetic Studies
The aim of this study was to investigate the association of SNPs of DGKD with parameters of glucose metabolism. The collection of subjects and the study protocol for our offspring study have been previously published (Salmenniemi et al., 2004) , and a summary is available (Supplemental Experimental Procedures). The study protocol was approved by the Ethics Committee of the University of Kuopio. All subjects gave an informed consent. The mean age and body mass index of the subjects was 35 years and 26 kg/m 2 , respectively, and all had nondiabetic glucose tolerance. Subjects underwent the following studies: an OGTT (n = 234), a euglycemic-hyperinsulinemic clamp (n = 217) to evaluate insulin sensitivity, and an intravenous glucose tolerance test (IVGTT) (n = 217) to evaluate the first phase insulin secretion. Selection of SNPs of DGKD was based on the genotype data from Utah residents with ancestry from Northern and Western Europe available from HapMap project's website (Public Release #20, January 24, 2006) (Altshuler et al., 2005) . Genotyping and statistical analysis are described (Supplemental Experimental Procedures).
Animal Studies
Animals were maintained in a temperature-and light-controlled environment and were cared for in accordance with regulations for the protection of laboratory animals. The regional animal ethical committee approved all experimental procedures. Animals were maintained under a 12 hr light:dark cycle and had free access to water and standard rodent chow.
Goto Kakizaki Rats and Treatment
Male GK and weight-matched Wistar rats (200-250 g) from Karolinska Institutet were treated with phlorizin (0.8 g/kg body weight per day; as 40% solution in propylene glycol) or vehicle (equal amounts of propylene glycol per kilogram) for 4 weeks (Krook et al., 1997) . Gastrocnemious muscle and liver were dissected and frozen in liquid nitrogen. Plasma insulin and glucose tolerance was previously determined (Krook et al., 1997) .
Epitrochlearis Muscle Incubation and Glucose Transport
Male Wistar rats (120-140 g) were obtained from B&K Universal, Sollentuna, Sweden. Rats were anesthetized with pentobarbital and epitrochlearis muscles were dissected free and incubated for insulin signaling and glucose transport. Muscles were preincubated for 30 min either with 50 mmol/l DGK inhibitor I R59022, 25 mmol/l DGK inhibitor II R59949, 1 mmol/l Phorbol-12-Myristate-13-Acetate (PMA), or broad spectrum PKC inhibitor GF109203X (1 mmol/l) (Calbiochem). Muscle was incubated for 30 min (Wallberg-Henriksson, 1987) in the absence or presence of 2.4 nmol/l insulin (Actrapid, Novo Nordisk) or incubated under a nitrogen gas phase (hypoxia) in the absence or presence of inhibitors. After incubation, muscles were frozen in liquid nitrogen for subsequent glucose transport and insulin signaling analysis. Glucose transport activity was assessed (Wallberg-Henriksson, 1987) .
Generation of DGKd Haploinsufficient Mice
The description of the methods used to generate haploinsufficient DGKd (DGKd +/À ) mice is presented in Crotty et al. (2006) .
Glucose Tolerance Test and Metabolic Analysis in DGKd +/À Mice
Glucose (1 g/kg body weight) was administered to fasted DGKd +/À mice and WT littermates by intraperitoneal injection (Supplemental Experimental Procedures). Plasma insulin, NEFA, adiponectin, leptin, and resistin were determined (Supplemental Experimental Procedures). 2-deoxy-glucose uptake and oleate oxidation were assessed in isolated mouse soleus muscle (Barnes et al., 2004) . Triglyceride content was determined in mouse gastrocnemius muscle using a triglycerides/glycerol blanked kit (Roche, Stockholm, Sweden) and a Seronorm lipid (SERO A/S, Oslo, Norway) standard.
Whole-Body Energy Homeostasis in DGKd +/À Mice
Food intake, oxygen consumption, RER, and locomotor activity were measured using a Comprehensive Lab Animal Monitoring System (Columbus Instruments, Columbus, OH, USA), (Supplemental Experimental Procedures).
Euglycemic-Hyperinsulinemic Clamp in Conscious in DGKd +/À Mice
Glucose turnover rate (GTR) was measured in the basal state and during euglycemic and hyperinsulinemic conditions, using a constant infusion of [3-3 H]glucose (Supplemental Experimental Procedures). Basal glucose production and utilization were assessed. Gastrocnemius muscle and liver were immediately frozen in liquid nitrogen for insulin signaling analysis.
Insulin-Stimulated Tissue-Specific Glucose Uptake in DGKd +/À Mice Animals were studied as described above for the Euglycemic-Hyperinsulinemic Clamp procedure. 2-deoxy-D-[1-
Analytical Procedures
Total DGK activity was determined (Lee et al., 1999 ) (Supplemental Experimental Procedures). Phosphorylation and expression of protein signaling intermediates and PI 3-kinase activity was assayed (Krook et al., 2000) . Skeletal muscle and liver DAG content was determined by conversion to phosphorylation products by externally added DAG-kinase from E. coli in the presence of [g-32 P] ATP (Preiss et al., 1986) . Total conventional and novel PKC activity was measured in muscle homogenates without addition of exogenous DAG (Kikkawa et al., 1983) . The specificity of the DGK inhibitor was tested against a panel of 30 different protein kinases ( Figure S4 ) (Davies et al., 2000) .
Statistics
Differences between groups were determined by ANOVA with multiple comparisons with Fischer's post hoc analysis. Student's t test was used for comparisons when only two parameters were evaluated. Correlations were determined using Pearson's Correlation Analysis. Significance was accepted at p < 0.05.
Supplemental Data
Supplemental Data include Experimental Procedures, four tables, and six figures and can be found with this article online at http://www.cell.com/cgi/ content/full/132/3/375/DC1/.
